ClinicalTrials.gg

Influenza, Human clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 2,360 studies for Influenza, Human across more than 10 countries. 185 are recruiting or about to start. 2,056 of them are mainly about Influenza, Human (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

ClinicalTrials.gov finds 2,739 studies for Influenza, Human. How that becomes 2,358 here

This page counts the studies the registry files under Influenza, Human, and those it files under no condition that list Influenza, Humanthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 16, 2026. How condition pages count

  1. 2,739Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −106List Influenza, Human as a condition, but the registry did not file them under itMost often written as “Influenza A” (28), “Influenza B” (13), and “Influenza Type B” (12). The registry filed them under other conditions only, most often COVID-19 (38) and Influenza in Birds (24).
  3. −275Match it another way235 name it in the title, 33 in a keyword, and 7 by a synonym or other text the search reads.
  4. 2,358The count on this page192 of them list Influenza, Human in their own words; the registry filed them under no condition.

Status

Completed
1,836
Status unknown
129
Recruiting
123
Terminated
82
Withdrawn
61
Active, not recruiting
60

Phase

Phase 2
542
Phase 3
462
Phase 1
438
Phase 4
365
Early Phase 1
7

Where

United States
966
China
173
Canada
157
United Kingdom
151
Germany
117
Belgium
106

Who develops what

Add Influenza, Human to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 58 programs from 24 companies, 50 with this as their studies’ main aim; 11 with a live phase 3 study; 15 primary completions in the next 12 months. Compare Sanofi, Sinovac Biotech and GlaxoSmithKline here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
Influenza VaccinesRecent, repeated
Evidence
  • NCT07805707 · GlaxoSmithKline · Phase 3 · live · comparator · “Licensed Influenza Vaccine” · registered Sep 2026
  • NCT06987942 · Sinovac Biotech Co., Ltd · Phase 4 · comparator · “TIV” · registered May 2025
  • NCT06864143 · Moderna, Inc. · Phase 2 · comparator · “Influenza Vaccine” · registered Mar 2025
  • NCT06694389 · Moderna, Inc. · Phase 3 · comparator · “Licensed Influenza Vaccine” · registered Nov 2024
  • NCT06602531 · Arcturus Therapeutics, Inc. · Phase 2 · comparator · “Control vaccine younger adults” · registered Sep 2024
—724 studies
OseltamivirRecent, repeated
Evidence
  • NCT07229807 · Guangdong Zhongsheng Pharmaceutical Co., Ltd. · Phase 3 · comparator · “Oseltamivir” · registered Nov 2025
  • NCT07113392 · Qingfeng Pharmaceutical Group Co., Ltd. · Phase 3 · live · comparator · “Oseltamivir” · registered Jul 2025
  • NCT04683406 · Guangdong Zhongsheng Pharmaceutical Co., Ltd. · Phase 3 · comparator · “Oseltamivir(oral)” · registered Dec 2020
  • NCT03028909 · AstraZeneca · Phase 2 · background · “Oseltamivir” · registered Dec 2016
  • NCT02949011 · Shionogi · Phase 3 · comparator · “Oseltamivir” · registered Oct 2016
Hoffmann-La Roche41% of its industry studiesUS: off-patent, 29 generics marketedEU: off-patent, 1 generic authorized22 studies
COVID-19 VaccinesRecent, repeated
Evidence
  • NCT06864143 · Moderna, Inc. · Phase 2 · comparator · “COVID-19 Vaccine” · registered Mar 2025
  • NCT06694389 · Moderna, Inc. · Phase 3 · comparator · “SARS-CoV-2 Vaccine” · registered Nov 2024
  • NCT06178991 · BioNTech SE · Phase 3 · comparator · “COVID-19 Vaccine” · registered Dec 2023
  • NCT06097273 · Moderna, Inc. · Phase 3 · comparator · “COVID-19 Vaccine” · registered Oct 2023
—24 studies

16 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
MRNA-1018☆ Track1 live phase-3 study: NCT07496450Moderna, Inc.
TG-1000☆ Track1 live phase-3 study: NCT07943390Boryung Biopharma Co., Ltd.
baloxavirApproved: US 2018 · EU 2021☆ Track2 live phase-3 studies: NCT06094010, NCT07827599Hoffmann-La Roche
efitazanamivir alfa☆ Track1 live phase-3 study: NCT07159763Merck & Co., Inc
mRNA Seasonal Flu vaccine☆ Track2 live phase-3 studies: NCT07851246, NCT07805707GlaxoSmithKline

The 5 in phase 3 with the nearest primary completion, of 58 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (15)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Nov 2026 est.tivoxavir marboxil · Traws Pharma, Inc. · Phase 2 main aimadded to influenza A virus subtype H1N1NCT07503405 Phase 2a Study of the Efficacy and Safety of TRX-100 in a Human Influenza A Challenge Model — primary endpoint: Laboratory-Confirmed Infection · 165 enrolled
  • Dec 2026 est.tivoxavir marboxil · Traws Pharma, Inc. · Phase 2 main aimNCT07371650 This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Tivoxavir Marboxil in Patients With Mild to Moderate Influenza — primary endpoint: Incidence of AE/SAE · 105 enrolled
  • 1 Dec 2026 est.Pandemic flu H5 HA mRNA SD2 vaccine · Sanofi · Phase 2 main aimNCT06907511 Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and Older — primary endpoint: Presence of immediate adverse events (AEs) · 720 enrolled

12 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Influenza, Human studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Corticosteroids 2 open · Statins 1 open · NSAIDs 1 open

Coming up

95studies finish main data collection within a year18 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 123 Influenza, Human studies recruiting now, 66 (54%) set no upper age limit and 47 (38%) stop at 75 or younger. 34 (28%) take children under 18. 3 (2%) are for women only and 0 (0%) for men only; 68 (55%) take healthy volunteers.

Recruiting studies that take each age, of 123
AgeWomenMen
1023 (19%)23 (19%)
1894 (76%)91 (74%)
3098 (80%)95 (77%)
4098 (80%)95 (77%)
5089 (72%)87 (71%)
6582 (67%)81 (66%)
7576 (62%)75 (61%)
8574 (60%)73 (59%)

Across all 2,360 studies, recruiting or not: 49% stop at 75 or younger and 47% at 65; 30% take children; 3% are for women only and 1% for men only; 72% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Influenza, Human studies take

Of 154 phase 3 interventional studies under Influenza, Human, half reached primary completion within 8 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 111 mo4–21 · 148 studies9 mo4–16 · 94 studies16 mo7–31 · 54 studies
Phase 1/212 mo7–16 · 43 studies13 mo7–16 · 41 studies—
Phase 210 mo5–19 · 122 studies7 mo5–14 · 86 studies19 mo9–56 · 36 studies
Phase 2/38 mo6–12 · 10 studies——
Phase 38 mo4–15 · 154 studies8 mo3–14 · 119 studies16 mo8–41 · 35 studies
Phase 414 mo3–37 · 138 studies3 mo2–6 · 37 studies19 mo5–52 · 101 studies
Interventional, no phase6 mo3–16 · 167 studies—7 mo3–18 · 147 studies
Observational23 mo7–59 · 135 studies10 mo2–34 · 37 studies36 mo12–92 · 98 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Newly registered18

Show 13 more

Studies

Recruiting first, then most recently updated. Showing 50 of 2,360. Browse all 2,360 → or search them.